These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9283399)

  • 1. Care of patients undergoing immunoglobulin therapy.
    Cochrane S
    Nurs Stand; 1997 Jul; 11(41):44-6. PubMed ID: 9283399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Effects of Immunoglobulin Therapy.
    Guo Y; Tian X; Wang X; Xiao Z
    Front Immunol; 2018; 9():1299. PubMed ID: 29951056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment with immunoglobulins].
    Junker U
    Z Arztl Fortbild Qualitatssich; 1999 Mar; 93(2):105-9. PubMed ID: 10355059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary embolism associated with intravenous immunoglobulin therapy.
    Butler KS; Zeitlin DS
    Ann Pharmacother; 2003 Oct; 37(10):1530. PubMed ID: 14519037
    [No Abstract]   [Full Text] [Related]  

  • 5. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America.
    Condino-Neto A; Costa-Carvalho BT; Grumach AS; King A; Bezrodnik L; Oleastro M; Leiva L; Porras O; Espinosa-Rosales FJ; Franco JL; Sorensen RU
    Allergol Immunopathol (Madr); 2014; 42(3):245-60. PubMed ID: 23333411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Will sialylation change intravenous immunoglobulin therapy in the future?
    Käsermann F; Campbell IK
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):100-2. PubMed ID: 25546779
    [No Abstract]   [Full Text] [Related]  

  • 7. Psoriasis improved by intravenous immunoglobulin therapy.
    Taguchi Y; Takashima S; Yoshida S; Dougu N; Inoue H; Tanaka K
    Intern Med; 2006; 45(14):879-80. PubMed ID: 16908947
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
    Sriaroon P; Ballow M
    Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunotherapy: the strategic approach to the treatment of patients with severe sepsis].
    Pidhirnyĭ IaM
    Klin Khir; 2005 Jul; (7):32-7. PubMed ID: 16255220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose intravenous immunoglobulin therapy in dysimmune neuropathies.
    Nobile-Orazio E; Bersano A
    Neurol Sci; 2002 Apr; 23 Suppl 1():S25-32. PubMed ID: 12032584
    [No Abstract]   [Full Text] [Related]  

  • 11. Osmotic demyelination syndrome: variable clinical and radiologic response to intravenous immunoglobulin therapy.
    Murthy SB; Izadyar S; Dhamne M; Kass JS; Goldsmith CE
    Neurol Sci; 2013 Apr; 34(4):581-4. PubMed ID: 22491911
    [No Abstract]   [Full Text] [Related]  

  • 12. [Intravenous immunoglobulin therapy].
    Mouthon L
    Rev Prat; 2005 May; 55(10):1049-56. PubMed ID: 16097244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Europe immunoglobulin map.
    Šedivá A; Chapel H; Gardulf A;
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):141-3. PubMed ID: 25546797
    [No Abstract]   [Full Text] [Related]  

  • 14. 7th International Immunoglobulin Conference: Poster presentations.
    Warnatz K; Ballow M; Stangel M; Bril V
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):162. PubMed ID: 25546805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunoglobulins and rules of passive-active prophylaxis].
    Bucholc B
    Przegl Epidemiol; 2003; 57(2):391-7. PubMed ID: 12910611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of adverse effects related to human immunoglobulin therapy: Recommendations for clinical practice].
    Marie I; Chérin P; Michallet M; Pelus E; Dantal J; Crave JC; Delain JC; Viallard JF
    Rev Med Interne; 2017 May; 38(5):312-319. PubMed ID: 27884454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing immunoglobulin G therapy in chronic autoimmune neuropathies.
    Berger M
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):144-5. PubMed ID: 25546798
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose and outcomes in primary immunodeficiency disorders.
    Bonagura VR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):7-9. PubMed ID: 25546743
    [No Abstract]   [Full Text] [Related]  

  • 19. Passive immunotherapy of sepsis with intravenous immune globulin: not all IVIg preparations are created equal.
    Vassilev T; Bauer M
    Crit Care; 2012 Jan; 16(1):407. PubMed ID: 22277798
    [No Abstract]   [Full Text] [Related]  

  • 20. Subcutaneous immunoglobulin: facilitated infusion and advances in administration.
    Wasserman RL
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):75-7. PubMed ID: 25546770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.